Several board-certified sleep specialists presented positive clinical data supporting use of Provent Sleep Apnea Therapy in their obstructive sleep apnea (OSA) patients. These presentations, at SLEEP 2011, highlighted the clinical efficacy and high compliance rate for patients with OSA using Provent Therapy.

“Together, these presentations provide conclusive evidence from clinical practices throughout the United States that Provent Therapy offers an effective treatment option for patients with obstructive sleep apnea who are not compliant on CPAP therapy,” said Philip Westbrook, MD, chief medical officer of Ventus Medical and Emeritus Clinical Professor of Medicine at the University of California, Los Angeles. “In addition to the consistent evidence of reduced apnea hypopnea index (AHI) and Epworth sleepiness scale (ESS), the presentations today include positive long-term (12-month) Provent Therapy results. We are excited to see how Provent Therapy is being used by sleep specialists across the country and incorporated into their therapeutic protocols for untreated patients suffering from obstructive sleep apnea.”

Meir Kryger, MD, of Gaylord Sleep Medicine in Wallingford, Conn, presented data from a 13-center, 12-month prospective study. Results showed that patients treated with Provent Therapy over a period of 12 months reduced their AHI by 70%. In addition, the study confirmed a very high nightly compliance rate of nearly 90%. Average ESS reduction was five points in addition to a 74% reduction in snoring for treated patients.

A poster presentation by Glenn Adams, MD, medical director for the Sleep Disorders Center at Sarasota Memorial Hospital in Sarasota, Fla, featured data using Provent Therapy in clinical practice. Adams showed that Provent Therapy when used alone or in combination with positional therapy (side sleeping) and/or chin straps was very effective in the treatment of OSA. AHI was reduced to less than 10 in more than 80% of patients (mild, moderate, and severe) using Provent Therapy, and over 90% of patients with mild to moderate OSA. Approximately 75% of patients acclimated to Provent Therapy within 10 days.

Additional poster presentations from Dennis Hwang, MD, of the Sleep Medicine Clinic at Kaiser Permanente in Fontana, Calif, and Clifford Massie, PhD, clinical director of the Chicago Sleep Group and Suburban Lung Associates, showed that in clinical practice, Provent Therapy is a viable alternative for patients with mild to moderate OSA who cannot tolerate CPAP therapy.

Finally, a poster presentation by Paula Schweitzer, PhD, director of research for the St Luke’s Sleep Medicine and Research Center, Chesterfield, Mo, analyzed pooled data from past clinical trials to conclude that Provent Therapy demonstrated a meaningful response in patients with OSA.